MedTrace Logo

The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema

NCT00358423 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2008-05-12

No results posted yet for this study

Summary

This research is being done to look at the effects of an experimental drug called pegaptanib (also called Macugen) for the treatment of swelling in the retina (the light sensitive tissue in the back of the eye) that can occur after cataract surgery. Swelling in the retina can lead to blurry vision.

The only treatment available for this condition is eye drops that decrease swelling in the back of the eye, but eye drops may not decrease the swelling in everyone. We want to see if pegaptanib can decrease swelling in the retina and improve vision in patients with swelling after cataract surgery.

Conditions

  • Cystoid Macular Edema

Interventions

DRUG

Pegaptanib Sodium

0.3 mg/0.1 ml intravitreal injection, every 6 weeks, up to a total of 3 injections

DRUG

Control

Sham injections, every 6 weeks, up to a total of 3 sham injections

Sponsors & Collaborators

Principal Investigators

  • Diana V. Do, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2007-02-28
Completion
2007-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00358423 on ClinicalTrials.gov